TheodorosMavri2 Profile Banner
Theodoros Mavridis Profile
Theodoros Mavridis

@TheodorosMavri2

Followers
98
Following
509
Media
8
Statuses
247

Neurologist MD, MSc, PhD • Consultant/Stroke and Headache Specialist at Tallaght University Hospital (TUH), Dublin • Research Associate at Eginition Hospital

Dublin, Ireland
Joined November 2019
Don't wanna be here? Send us removal request.
@TheodorosMavri2
Theodoros Mavridis
3 days
RT @IntJStroke: Just Accepted!.🌎🧠A Scientific Statement from the International CAA Association and the World Stroke Organization. 🧠Diagnosi….
Tweet card summary image
journals.sagepub.com
Cerebral amyloid angiopathy (CAA) is a well-recognized and challenging disease for neurologists and other clinicians caring for the rapidly aging worldwide popu...
0
17
0
@TheodorosMavri2
Theodoros Mavridis
6 days
🆕 New Publication.Can anticoagulant choice protect your kidneys? 🧠🩸.Our systematic review & meta-analysis shows that DOACs delay renal function decline in patients with atrial fibrillation compared to VKAs. 📖 Read the full open-access article:.
0
0
1
@TheodorosMavri2
Theodoros Mavridis
19 days
Excited to present our newly published study/meta-analysis on LAAO in patients with previous ICrH and/or CAA. Many thanks to my mentor @a_charidimou. Without his guidance this endeavor would not be possible. I also want to thank Dr Archontakis-Barakakis and Dr Chlorogiannis. .
@IntJStroke
International Journal of Stroke
20 days
Just Accepted!.🫀🩸Systematic review and meta-analysis suggests LAAO may offer safe and feasible alternative to anticoagulation in high bleeding risk AF patients with ICrH/ CAA. 👉More RCTs needed to confirm. Read more here!👇.@TheodorosMavri2
Tweet media one
0
4
8
@TheodorosMavri2
Theodoros Mavridis
20 days
New Insights on Migraine Prevention!. A fresh analysis comparing Gepants, anti-CGRP monoclonal antibodies, and traditional preventives reveals a clearer picture of benefit vs. risk in migraine care. Click the link below to learn more.
tandfonline.com
Gepants, selective antagonists of the calcitonin gene-related peptide (CGRP) receptor, and monoclonal antibodies targeting CGRP or its receptor (anti-CGRP mAbs) are promising migraine treatments, d...
0
0
1
@TheodorosMavri2
Theodoros Mavridis
1 month
RT @WorldStrokeEd: #MondayTip.📊Pooled INTERACT data. ✅Intensive BP lowering improves recovery in ICH.⏱️When started <3h (cutoff: 2.6h)➡️red….
0
39
0
@TheodorosMavri2
Theodoros Mavridis
2 months
RT @ESOstroke: Technical skills are important to influence the patient outcome. 👫 Strokecare is teamwork. Bastian Volbers from @inselgr….
0
8
0
@TheodorosMavri2
Theodoros Mavridis
2 months
I’m honoured to be running for IHS Trustee!. I’m passionate about raising awareness and improving headache education, locally and globally. I’d be truly grateful for your support if you are eligible to vote (emails automatically sent) — and please feel free to share this post!
Tweet media one
0
1
3
@TheodorosMavri2
Theodoros Mavridis
3 months
It was an honour to present our on ICH and/or CAA treated with LAAO work at #ESOC2025. 🔬.Special thanks to my mentor @a_charidimou and of course my colleagues, Paraschos Archontakis Barakakis and David Dimitris Chlorogiannis for the support. #VoiceOfStroke @ESOstroke.
1
0
5
@TheodorosMavri2
Theodoros Mavridis
3 months
RT @chris7ianb: @a_charidimou kicks off #ESOC2025 @ESOstroke with a fine talk on application of diagnostic criteria in CAA .
0
11
0
@TheodorosMavri2
Theodoros Mavridis
3 months
RT @ESOstroke: #ESOC2025 | What a Day 1!.Full sessions, knowledge exchange & strong engagement across the #stroke community. Catch takeaway….
0
10
0
@TheodorosMavri2
Theodoros Mavridis
4 months
RT @JohannaSeidenMD: Here's a review on some of the inherited thrombophilias that are frequently ordered as part of the hypercoagulability….
0
27
0
@TheodorosMavri2
Theodoros Mavridis
4 months
RT @a_charidimou: 🩸🧠User friendly version of Boston Criteria v2.0 for Sporadic Cerebral Amyloid Angiopathy (CAA). #NeuroTwitter #Neurolog….
0
49
0
@TheodorosMavri2
Theodoros Mavridis
4 months
New Paper 📃. This review examines the role of RGMa in CNS pathologies such as stroke, Alzheimer’s disease, Parkinson’s disease, ALS, multiple sclerosis, NMOSD, spinal cord injury and more. Congrats one more time to @v_tseriotis. #mdpiijms via @IJMS_MDPI.
Tweet card summary image
mdpi.com
Repulsive guidance molecule-a (RGMa) has emerged as a significant therapeutic target in a variety of neurological disorders, including neurodegenerative diseases and acute conditions. This review...
0
1
7
@TheodorosMavri2
Theodoros Mavridis
4 months
RT @RCMjournal: #RCM - Vol. 23 No. 10.🗳️Systematic Review.Major Hemorrhage Risk Associated with Direct Oral Anticoagulants in Non-Valvular….
0
5
0
@TheodorosMavri2
Theodoros Mavridis
4 months
RT @a_charidimou: ⭕️🧠 CAA progression & neuropath staging (CAA=Cerebral Amyloid Angiopathy) . Here is my take👇 which will try to unpack….
0
23
0
@TheodorosMavri2
Theodoros Mavridis
5 months
RT @a_charidimou: ⚡️🩸🧠 Practical framework for diagnosing Cerebral Amyloid Angiopathy-related inflammation (CAA-ri). We frequently discuss….
0
39
0
@TheodorosMavri2
Theodoros Mavridis
5 months
RT @Fie0815: Secondary TENSION RCT analysis: EVT works with good and poor collaterals in large core stroke. No significant difference. http….
0
13
0
@TheodorosMavri2
Theodoros Mavridis
5 months
RT @MASStroke: Week 2 of the @MASStroke kicks off in Bern! Inspiring lectures, interactive courses, lively discussions—and plenty of networ….
0
13
0